✨ Free AI Report
bioMérieux S.A.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research bioMérieux S.A.
Company Research

bioMérieux S.A.: Business Overview, Financials & Competitive Analysis

bioMérieux S.A. scores 7/10 on the AskCyborg Cyborg Score (Strong). Specialized diagnostics leader with niche market dominance and diversified revenue streams, trading at premium valuations reflecting growth prospects in precision diagnostics and food safety sectors. bioMérieux holds strong market leadership in specialized niches with a diversified product portfolio and global presence across 44 countries. Growth is supported by innovation and.

What is bioMérieux S.A.'s industry? bioMérieux S.A. (biomerieux.com) operates in In Vitro Diagnostics (IVD) / Clinical Laboratory Diagnostics. AskCyborg classifies bioMérieux S.A. under In Vitro Diagnostics (IVD) / Clinical Laboratory Diagnostics in its company registry.

bioMérieux is a French multinational biotechnology company founded and headquartered in Marcy-l'Étoile, France, that provides diagnostic solutions (reagents, instruments, software, services) which determine the source...

7/ 10Strong

Cyborg Score thesis

Specialized diagnostics leader with niche market dominance and diversified revenue streams, trading at premium valuations...

Read the full analyst-debate transcript →
Industry In Vitro Diagnostics (IVD) / Clinical Laboratory Diagnostics
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest bioMérieux S.A. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for bioMérieux S.A.

AskCyborg analysts argue the bull and bear cases for bioMérieux S.A. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
bioMérieux S.A. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

bioMérieux S.A. Overview

Pro stress-test →

bioMérieux is a French multinational biotechnology company founded and headquartered in Marcy-l'Étoile, France, that provides diagnostic solutions (reagents, instruments, software, services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. The company's products are used for diagnosing infectious diseases, cancer screening, and monitoring and cardiovascular emergencies, as well as detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

Strategic Profile

Pro stress-test →

bioMérieux is a specialist in the fragmented in vitro diagnostics market with expertise in microbiology testing and syndromic molecular testing, positioning the company as a leader in niche markets that allows it to grow faster than the in vitro diagnostics market. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%).

Competitive Landscape

Pro stress-test →

bioMérieux competes against 18 competitors including Bio-Rad Laboratories. The company's strength lies in niche market expertise rather than competing on volume, with specialized capabilities in microbiology, molecular diagnostics, and industrial contamination detection that differentiate it from larger generalist diagnostics players.

Industry Context

bioMérieux S.A. operates in In Vitro Diagnostics (IVD) / Clinical Laboratory Diagnostics.

Key facts

Founded: 1963 · Headquarters: Marcy-l'Étoile, France · Employees: 10000+ · Revenue: $4.48B · Market cap: $14.8B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on bioMérieux S.A..

  • Molecular biology segment is largest revenue driver at 42% of sales, reflecting industry shift toward advanced diagnostics
  • Strong geographic diversification with Americas (40% of revenue), Asia-Pacific (27%), and EMEA (27%), reducing geographic concentration risk
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • December 2025BIOFIRE SPOTFIRE point-of-care diagnostics platform study enrollment launching in Q1 2026 across US and UK markets
  • November 2025Capital Markets Day unveiled GO•28 strategic plan, the new 5-year growth and development chapter for the company
  • +1 moreTrack every material event for bioMérieux S.A. as it happens. Explore monitoring →
Get alerted when bioMérieux S.A. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Bio-Rad LaboratoriesComprehensive clinical diagnostics and life science research→Abbott DiagnosticsBroad-based point-of-care and laboratory diagnostics→Becton DickinsonClinical and industrial microbiology systems→Roche DiagnosticsIntegrated diagnostics and pharmaceutical solutions→

Compare bioMérieux S.A. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

bioMérieux S.A. operates in In Vitro Diagnostics (IVD) / Clinical Laboratory Diagnostics. See how the rest of the sector scores on the Cyborg framework.

Browse In Vitro Diagnostics (IVD) / Clinical Laboratory Diagnostics research →
NEW · MCP server

Ask your AI assistant about bioMérieux S.A.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare bioMérieux S.A. and its top competitor on Cyborg Score”
“What did bioMérieux S.A. do this quarter?”
“Is bioMérieux S.A. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does bioMérieux S.A. do?+
bioMérieux is a French multinational biotechnology company founded and headquartered in Marcy-l'Étoile, France, that provides diagnostic solutions (reagents, instruments, software, services) which determine the source...
What is bioMérieux S.A.'s Cyborg Score?+
bioMérieux S.A. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are bioMérieux S.A.'s main competitors?+
Named competitors include Bio-Rad Laboratories, Abbott Diagnostics, Becton Dickinson, Roche Diagnostics. The full competitive landscape is in the AskCyborg report.
How can I get the full bioMérieux S.A. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the bioMérieux S.A. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track bioMérieux S.A. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More In Vitro Diagnostics (IVD) research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7bioMérieux S.A.7Eurobio Scientific7Gentian Diagnostics ASA5BioPorto A/S5EKF Diagnostics Holdings plc4OraSure Technologies, Inc.